Share price · CASIF
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CASIF's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 7 Jul 2026-35.0%
Nothing announced by CASIF that day or the session before.
- 6 Jul 2026+33.3%
Nothing announced by CASIF that day or the session before.
- 2 Jul 2026-37.5%
Nothing announced by CASIF that day or the session before.
- 1 Jul 2026+41.2%
Nothing announced by CASIF that day or the session before.
- 30 Jun 2026+41.7%
- Day before6-K filing
- 24 Jun 2026-33.3%
Nothing announced by CASIF that day or the session before.
- 12 Jun 2026+42.9%
Nothing announced by CASIF that day or the session before.
- 11 Jun 2026+27.3%
Nothing announced by CASIF that day or the session before.
- 9 Apr 2026-29.4%
Nothing announced by CASIF that day or the session before.
- 31 Mar 2026-31.3%
Nothing announced by CASIF that day or the session before.
Share of unusual movement by asset
For each asset, the share of CASIF's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
CID-103events and moves
| 2 | shown from 8 days |
melphalan hydrochloride (Evomela)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 5% |
| Other company news (earnings, financing, releases naming no asset) | — | 22% |
| Sessions with no dated event | — | 73% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | DNA (guanine N7 position)Small molecule | Multiple Myeloma Autologous Stem Cell Conditioning in Multiple Myeloma | |
| Phase 2 | CD38Monoclonal antibody | Multiple MyelomaImmune Thrombocytopenia |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
Financial reports
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $21M | $6.3M | $5.6M | $12M-$21M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $29M | $8.9M | $13M | $9.8M-$29M operating cash flow | report ↗ |
| 2023-FY | $34M | $9.9M | $17M+ $12M short-term inv. | $6.7M-$20M operating cash flow | report ↗ |
| 2022-FY | $43M | $16M | $47M+ $2.8M short-term inv. | $10M-$21M operating cash flow | report ↗ |
| 2021-FY | $30M | — | $39M+ $9.9M short-term inv. | $9.2M-$27M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
No Form 4 transactions on file in the stored window.